Received Aug 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | 1 | LF5308 | LA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 9X7CD | RA |
Localized erythema; Headaches; This is a spontaneous report received from a Consumer or other non HCP. A 16-year-old male patient received meningococcal group b Rlp2086 (TRUMENBA), on 13Aug2025 as dose 1, single (Lot number: LF5308) at the age of 16 years, in left arm for immunisation; meningococcal vaccine a/c/y/w conj (CRM197) (MENVEO), on 13Aug2025 as dose 2, single (Lot number: 9X7CD), in right arm. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: HEADACHE (non-serious) with onset 14Aug2025, outcome "recovering", described as "Headaches"; ERYTHEMA (non-serious) with onset 14Aug2025, outcome "recovering", described as "Localized erythema". Therapeutic measures were taken as a result of erythema, headache. Additional information: The patient did not receive any other vaccines within 4 weeks PRIOR to the vaccine(s) for which they were reporting. The patient was not taking any other medications within 2 weeks of the event starting. Treatment included IBUPROFEN 800 mg three times a day.
Comments: List of non-encoded Patient Relevant History: Patient Other Relevant History 1: None